Skip to product information
1 of 1

  • Gphc Registered
  • Join over 100k customers
  • Fixed prices and no subscriptions
  • Discreet next day delivery.
  • Free shipping on all orders over £50

OMRON Deluxe Tens Pulse Massager E3

OMRON Deluxe Tens Pulse Massager E3

  • Ozempic®️-equivalent therapy now available for weight management
  • Average weight loss of 17%, with 1 in 3 patients achieving over 20%
  • May help reduce osteoarthritis-related pain
  • Wegovy®️ is not expected to impact the effectiveness of oral contraceptives
  • Supports cardiovascular risk reduction
  • Over 22 million patients treated with semaglutide-based therapies since 2018

We’re proud to offer fast and discreet delivery for all our medicines & treatments.

Price Checker

Regular price £55.99
Sale price £55.99
Sale Sold out
  • Lowest price guarantee
  • Includes FREE private prescription
View full details

 The OMRON Deluxe Tens Pulse Massager E3 stands as a compact yet powerful device that delivers TENS (Transcutaneous Electrical Nerve Stimulation) technology to provide pain relief and relaxation. The E3 delivers specific therapy to address muscle tension joint pain and general discomfort for users who need pain relief and recovery support. Users can customize their experience by adjusting multiple intensity levels and settings to meet their individual needs for maximum comfort and effectiveness.

  • The device features a modern portable design which allows  users to operate it both at home and during travel while its clear display and simple controls provide an accessible  experience for all users.
  • The OMRON Deluxe Tens Pulse Massager E3 features multiple  pre-programmed modes which provide solutions for various pain types including relaxation and muscle stimulation.
  • The OMRON  Deluxe Tens Pulse Massager E3 serves as a versatile essential tool for natural pain management without drugs  which benefits athletes and office workers and everyone who wants to enhance their wellness and life quality.

Patient Information Leaflet

Important - Before taking any medication, it is always important to read the Patient Information Leaflet (PIL)

Written and reviewed by our qualified team

GPhC Number: 2088658
Muzammil Peerally

Authored by:

Muzammil Peerally

Superintendent Pharmacist

GPhC Number: 2232689
Tarun Kumar

Reviewed by:

Tarun Kumar

Clinical Leads

📖 Find out more about our team of medical content authors and how we ensure the accuracy of our content with our content guidelines.

Content last updated: 31 Mar 2025

We’re a safe and
regulated UK service

Registered Pharmacy Badge

Lowest Price Guarantee

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

100% discreet packaging

We're convinced you won't find your treatment cheaper, but if you do we'll refund the difference.

Find out more

Agent

Need help?
Talk to our friendly experts now

How our service works

Service Setup

Service setup

Discreet Packaging

Discreet packaging

Express Delivery

Express delivery

Comparison of Weight Loss Injectables

Features

Mounjaro®

Injectable Pen

Wegovy®

Injectable Pen

Saxenda®

Injectable Pen

Active Ingredient Tirzepatide Semaglutide Liraglutide
Mechanism of Action GLP-1 and GIP receptor agonist GLP-1 receptor agonist GLP-1 receptor agonist
Administration Weekly injection Weekly injection Daily injection
Dosage Varies by patient, typically starting low Varies, typically starting at 0.25 mg Varies, starting at 0.6 mg
Effect on Appetite Significantly reduces appetite and cravings Reduces appetite and increases satiety Reduces appetite and increases satiety
Average Weight Loss Up to 20% body weight reduction Up to 15% body weight reduction Significant weight reduction
Side Effects Nausea, vomiting, diarrhoea, constipation Nausea, vomiting, diarrhoea, constipation Nausea, diarrhoea, constipation, hypoglycemia
Approval FDA-approved for weight loss FDA-approved for weight loss FDA-approved for weight loss
Suitable For Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities Adults with BMI ≥30 or ≥27 with comorbidities